These decreases in LFC are broadly in line with those reported in phase 3 studies of the approved THRβ agonist resmetirom in patients with MASH, who achieved reductions of 40.8–49.0% over 16 weeks, and 35.4–46.6% over 52 weeks19,29. Here, THRB is linked to metabolic dysfunction-associated steatohepatitis.